 | Leslie Jay KatzShow email addressWills Eye Hospital, Thomas Jefferson University, Philadelphia, USA. | Wills Eye Hospital, Glaucoma Research Center, Philadelphia, Pennsylvania | Glaukos, San Clemente, ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
Leslie Jay Katz:Expert Impact
Concepts for whichLeslie Jay Katzhas direct influence:Intraocular pressure,Ocular hypertension,Glaucoma patients,Angle glaucoma,Visual field,Optic disc,Istent inject,Glaucoma specialists.
Leslie Jay Katz:KOL impact
Concepts related to the work of other authors for whichfor which Leslie Jay Katz has influence:Intraocular pressure,Ocular hypertension,Angle glaucoma,Cataract surgery,Selective laser trabeculoplasty,Optic nerve,Visual acuity.
KOL Resume for Leslie Jay Katz
| Year | |
|---|---|
| 2022 | Wills Eye Hospital, Thomas Jefferson University, Philadelphia, USA. |
| 2021 | Wills Eye Hospital, Glaucoma Research Center, Philadelphia, Pennsylvania Glaukos, San Clemente, California, USA (H.F., L.J.K.). Department of Ophthalmology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA |
| 2020 | Glaucoma Service, Wills Eye Hospital, Philadelphia, PA Department of Ophthalmology, Wills Eye Hospital, Jefferson Medical College , Philadelphia, Pennsylvania, USA. Glaukos Corporation, San Clemente, California, USA |
| 2019 | William and Anna Goldberg Glaucoma Service and Wills Eye Institute, Jefferson Medical College, Philadelphia, Pennsylvania, USA Wills Eye Hospital, Glaucoma Research Center, Philadelphia, PA; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA. Glaukos Corporation, San Clemente, California |
| 2018 | Glaucoma Research Center (K.R., S.S.W., M.R.M., L.A.H., L.J.K.), Wills Eye Hospital, Philadelphia, PA; and Cornea Department (C.J.R.), Wills Eye Hospital, Philadelphia, PA; Formerly Glaucoma Research Center (P.I.), Wills Eye Hospital, Philadelphia, PA; Currently Department of Ophthalmology (P.I.), Government Medical College and Hospital, Chandigarh, India. Sidney Kimmel Medical College, Thomas Jefferson University. Wills Eye Hospital, Philadelphia, PA, USA, View further author information Thomas Jefferson University, Department of Ophthalmology, Philadelphia, PA |
| 2017 | Department of Ophthalmology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania Wills EyeHospital Glaucoma Research Center, Philadelphia, PA 19107, USA. |
| 2016 | Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA 19107, USA |
| 2015 | Glaucoma Service, Wills Eye Institute, Philadelphia, PA 19107; Wills Eye Hospital, Jefferson Medical College, Philadelphia, PA, USA |
| 2014 | Glaucoma Research Center, William and Anna Goldberg Glaucoma Service, Wills Eye Hospital, Philadelphia, Pennsylvania, USA |
| 2013 | Department of Ophthalmology (Dr Katz) and the Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics (Dr Leiby), Jefferson Medical College, Thomas Jefferson University; Wills Eye Institute (Dr Katz and Dr Zangalli); and Drexel University College of Medicine (Mr Clifford). |
| 2012 | Glaucoma Service, Wills Eye Institute, Philadelphia, PA, USA Wills Eye Hospital Philadelphia, |
| 2011 | Glaucoma Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, PA, USA Wills Eye Institute, Thomas Jefferson University, Philadelphia, Pennsylvania |
| 2010 | Wills Eye Institute, Jefferson Medical College, 840 Walnut Street, Suite 1140, Philadelphia, PA 19107, USA +1 215 928 3197; +1 215 928 3285; |
| 2009 | William and Anna Goldberg Glaucoma Service, Wills Eye Hospital, Thomas Jefferson University Hospital, Philadelphia, PA Glaucoma Service, Wills Eye Institute, Jefferson Medical College, Philadelphia, Pennsylvania |
| 2008 | University of California, Davis, Sacramento, CA Director, William and Anna Goldberg Glaucoma Service and Research Center, Wills Eye Institute, Professor of Ophthalmology, Jefferson Medical College 840 Walnut St. Ste. 1130, Philadelphia, PA 19107, USA Glaucoma Department, Wills Eye Institute, Jefferson Medical College, Philadelphia, PA |
| 2007 | Wills Eye Hospital, Thomas Jefferson Medical School, Philadelphia, PA, USA; and |
| 2006 | Wills Eye Hospital, Philadelphia, Pa (Drs Katz and Myers) Massachusetts Eye and Ear Infirmary, Boston, MA, USA |
| 2005 | William and Anna Goldberg Glaucoma Service, Wills Eye Hospital, Jefferson Medical College, Philadelphia, Pennsylvania, USA Glaucoma Service, Wills Eye Hospital, Philadelphia, Pennsylvania. |
| Concept | World rank |
|---|---|
| satisfaction rating brimonidinepurite | #1 |
| eyes interno implantation | #1 |
| complete eye exam | #1 |
| pregnancy glaucoma | #1 |
| filtering surgeries patients | #1 |
| 24 diop | #1 |
| ≤15 mmhg travoprost | #1 |
| stents topical | #1 |
| 45 292 | #1 |
| postoperative prostaglandin | #1 |
| glaucoma nonsteroidal medications | #1 |
| medications unmedicated | #1 |
| text new pictures | #1 |
| osdi composite scores | #1 |
| multistent eyes iop | #1 |
| qualified success reduction | #1 |
| conjunctivitis satisfaction | #1 |
| trabecular stents | #1 |
| months brimonidine | #1 |
| unmedicated baseline iop | #1 |
| evening angle | #1 |
| slt medications | #1 |
| holmium publication administration | #1 |
| repeat slt laser | #1 |
| medication filtering | #1 |
| blebassociated infection trabeculectomy | #1 |
| twentynine investigational sites | #1 |
| druginduced glaucoma cases | #1 |
| greater extent scale | #1 |
| medications stent | #1 |
| 62 341 | #1 |
| glaucomarelated pathology | #1 |
| 5year effectiveness | #1 |
| istents slt | #1 |
| brimonidine dorzolamide | #1 |
| eyes inj eyes | #1 |
| inclusion criteria eye | #1 |
| year istents | #1 |
| nonioprelated risk factors | #1 |
| glaucoma direct damage | #1 |
| appointments methods | #1 |
| eyes medical therapy | #1 |
| choroidal effusion eyes | #1 |
| 05 ocular | #1 |
| mitomycinc complications | #1 |
| follow philadelphia | #1 |
| stents ocular | #1 |
| options independent | #1 |
| standalone procedure iop | #1 |
| Sign-in to see all concepts, it's free! | |
Prominent publications by Leslie Jay Katz
PURPOSE: To evaluate the safety and efficacy of a fixed combination (FC) of bimatoprost (BIM) and timolol (TIM) compared with each of the active components for 3 months.
PATIENTS AND METHODS: Two double-masked, randomized, multicenter parallel studies of FC (once-daily, mornings), BIM (once-daily, evenings), or TIM (twice-daily) were conducted in 1061 patients with glaucoma or ocular hypertension.
RESULTS: Mean diurnal decreases from baseline intraocular pressure (IOP) at month 3 were ...
| Known for Ocular Hypertension | Fixed Combination | Bim Tim | Individual Components | Patients Glaucoma |
PURPOSE: To assess the long-term safety and efficacy of a single trabecular micro-bypass stent with concomitant cataract surgery versus cataract surgery alone for mild to moderate open-angle glaucoma.
SETTING: Twenty-nine investigational sites, United States.
DESIGN: Prospective randomized controlled multicenter clinical trial.
METHODS: Eyes with mild to moderate glaucoma with an unmedicated intraocular pressure (IOP) of 22 mm Hg or higher and 36 mm Hg or lower were randomly assigned to ...
| Known for Cataract Surgery | Stent Implantation | 24 Months | Trabecular Micro | Patients Iop |
Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients
[ PUBLICATION ]
PURPOSE: To compare the long-term efficacy and safety of brimonidine 0.2% twice daily with timolol 0.5% twice daily in patients with glaucoma or ocular hypertension.
METHODS: Of the 926 patients enrolled in the study, 837 met the protocol entry criteria and received either brimonidine 0.2% twice daily (n = 466) or timolol 0.5% (n = 371) twice daily in each eye for 1 year.
RESULTS: Brimonidine and timolol significantly reduced mean intraocular pressure (P < .001) from baseline levels at ...
| Known for Brimonidine Timolol | Glaucoma Patients | Heart Rate | Intraocular Pressure | Ocular Hypertension |
OBJECTIVE: To detect and quantitate changes in optic nerve morphology after glaucoma surgery using the Heidelberg Retina Tomograph (HRT, Heidelberg Instruments, Heidelberg, Germany).
DESIGN: Nonconsecutive observational case series.
PARTICIPANTS AND INTERVENTION: The authors prospectively enrolled 21 adult patients undergoing incisional glaucoma surgery for progressive glaucoma damage. Quantitative analysis of the optic nerve head by scanning laser tomography and automated perimetry were ...
| Known for Glaucoma Surgery | Optic Disc | Intraocular Pressure Iop | Retina Tomograph | Ratio Cup |
PURPOSE: To evaluate the efficacy and ocular and systemic safety of netarsudil 0.02% ophthalmic solution, a rho-kinase inhibitor and norepinephrine transporter inhibitor, in patients with open-angle glaucoma and ocular hypertension.
DESIGN: Double-masked, randomized noninferiority clinical trials: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).
METHODS: After a washout of all pre-study ocular hypotensive medications, eligible patients were randomized to receive ...
| Known for Rho Kinase | Intraocular Pressure | Netarsudil Timolol | Iop Treatment Trial | Openangle Glaucoma |
Selective Laser Trabeculoplasty Versus Medical Therapy as Initial Treatment of Glaucoma
[ PUBLICATION ]
PURPOSE: To compare outcomes of selective laser trabeculoplasty (SLT) with drug therapy for glaucoma patients in a prospective randomized clinical trial.
PATIENTS AND METHODS: Sixty-nine patients (127 eyes) with open-angle glaucoma or ocular hypertension were randomized to SLT or medical therapy. Target intraocular pressure (IOP) was determined using the Collaborative Initial Glaucoma Treatment Study formula. Patients were treated with SLT (100 applications 360 degrees) or medical ...
| Known for Medical Therapy | Initial Treatment | Selective Laser | Patients Slt | Iop Eyes |
IMPORTANCE: Additional data are sought regarding treatment options for glaucoma, a major cause of global blindness.
BACKGROUND: The study assessed outcomes following standalone implantation of two second-generation trabecular micro-bypass stents and postoperative topical prostaglandin in eyes with open-angle glaucoma not controlled on two preoperative medications.
DESIGN: The study design is a prospective, nonrandomized, open-label study at a tertiary-care ophthalmology ...
| Known for Angle Glaucoma | Generation Trabecular | Medication Eyes | Topical Travoprost | Intraocular Pressure |
Twelve-Month Evaluation of Brimonidine-Purite Versus Brimonidine in Patients With Glaucoma or Ocular Hypertension
[ PUBLICATION ]
PURPOSE: To compare the efficacy and safety of brimonidine-Purite (Alphagan; Allergan, Irvine, CA) 0.15% and 0.2% three times daily with brimonidine (Alphagan) 0.2% three times daily in patients with glaucoma or ocular hypertension.
PATIENTS AND METHODS: In this 12-month, randomized, multicenter, double-masked, parallel-group study, patients were randomly assigned to receive brimonidine-Purite 0.15% (n = 381), brimonidine-Purite 0.2% (n = 383), or brimonidine 0.2% (n = 383) three times ...
| Known for Ocular Hypertension | Patients Glaucoma | Allergic Conjunctivitis | Brimonidine Purite | 6 Months |
PURPOSE: To evaluate the long-term intraocular pressure (IOP)-lowering effect and safety parameters following treatment with two trabecular micro-bypass stents and topical prostaglandin in phakic eyes with open-angle glaucoma (OAG) not controlled on two preoperative medications.
METHODS: This prospective, single-arm, unmasked study enrolled 39 qualified phakic eyes with OAG not controlled on 2 medications, preoperative medicated IOP of 18-30 mmHg, and IOP following medication washout of ...
| Known for Bypass Stents | Trabecular Micro | 1 Medication | Eyes Iop | Angle Glaucoma |
Randomized Evaluation of the Trabecular Micro-Bypass Stent with Phacoemulsification in Patients with Glaucoma and Cataract
[ PUBLICATION ]
OBJECTIVE: To assess the safety and efficacy of the iStent trabecular micro-bypass stent (Glaukos Corporation, Laguna Hills, CA) in combination with cataract surgery in subjects with mild to moderate open-angle glaucoma.
DESIGN: Prospective, randomized, open-label, controlled, multicenter clinical trial.
PARTICIPANTS: A total of 240 eyes with mild to moderate open-angle glaucoma with intraocular pressure (IOP) ≤24 mmHg controlled on 1 to 3 medications were randomized to undergo cataract ...
| Known for Cataract Surgery | 1 Year | Trabecular Micro | Bypass Stent | Treatment Eyes |
Twelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular Hypertension
[ PUBLICATION ]
PURPOSE: To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of ophthalmic formulations of bimatoprost 0.01% and 0.0125% compared with bimatoprost 0.03%.
DESIGN: Prospective, randomized, double-masked, multicenter clinical trial.
METHODS: Patients with glaucoma or ocular hypertension were randomized to receive once-daily bimatoprost 0.01% (n = 186), bimatoprost 0.0125% (n = 188), or bimatoprost 0.03% (n = 187) for 12 months. The primary efficacy measure was IOP. ...
| Known for Bimatoprost 001 | Ocular Hypertension | 003 Patients | 12 Months | Amides Antihypertensive Agents |
PURPOSE: Evaluate the safety and effectiveness of an ab interno implanted (iStent inject) Trabecular Micro-Bypass System (Glaukos Corporation, San Clemente, CA) in combination with cataract surgery in subjects with mild to moderate primary open-angle glaucoma (POAG).
DESIGN: Prospective, randomized, single-masked, concurrently controlled, multicenter clinical trial.
PARTICIPANTS: Eyes with mild to moderate POAG and preoperative intraocular pressure (IOP) ≤24 mmHg on 1 to 3 medications, ...
| Known for Angle Glaucoma | Cataract Surgery | Trabecular Micro | Baseline Month | 2 Years |
Purpose: Evaluate long-term outcomes after one, two, or three trabecular micro-bypass stents implanted in a standalone procedure in eyes with open-angle glaucoma taking ocular hypotensive medication.
Patients and methods: Prospective randomized ongoing study of 119 subjects (109 with 42-month follow-up) with open-angle glaucoma, preoperative intraocular pressure (IOP) 18-30 mmHg on one to three glaucoma medications, and unmedicated (post-washout) IOP 22-38 mmHg. Subjects were randomized ...
| Known for Angle Glaucoma | Iop Medication | Trabecular Micro | Stent Eyes | Standalone Procedure |
